Douglass Winthrop Advisors LLC Sells 270 Shares of Johnson & Johnson (NYSE:JNJ)

Douglass Winthrop Advisors LLC reduced its holdings in Johnson & Johnson (NYSE:JNJGet Rating) by 0.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 125,996 shares of the company’s stock after selling 270 shares during the period. Douglass Winthrop Advisors LLC’s holdings in Johnson & Johnson were worth $22,366,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the business. RE Dickinson Investment Advisors LLC grew its holdings in shares of Johnson & Johnson by 163.3% during the 1st quarter. RE Dickinson Investment Advisors LLC now owns 158 shares of the company’s stock worth $28,000 after purchasing an additional 98 shares in the last quarter. Advanced Research Investment Solutions LLC grew its holdings in shares of Johnson & Johnson by 200.0% during the 1st quarter. Advanced Research Investment Solutions LLC now owns 180 shares of the company’s stock worth $32,000 after purchasing an additional 120 shares in the last quarter. Morton Brown Family Wealth LLC grew its holdings in shares of Johnson & Johnson by 78.0% during the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after purchasing an additional 78 shares in the last quarter. Professional Financial Advisors LLC grew its holdings in shares of Johnson & Johnson by 47.9% during the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company’s stock worth $37,000 after purchasing an additional 68 shares in the last quarter. Finally, Goodman Advisory Group LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $39,000. 68.59% of the stock is owned by institutional investors.

Insider Transactions at Johnson & Johnson

In other news, EVP Jennifer L. Taubert sold 76,923 shares of the business’s stock in a transaction on Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction dated Tuesday, November 22nd. The stock was sold at an average price of $176.78, for a total value of $13,598,447.94. Following the completion of the sale, the executive vice president now owns 126,456 shares in the company, valued at $22,354,891.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Thibaut Mongon sold 35,246 shares of the stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total value of $6,033,410.28. Following the completion of the sale, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The disclosure for this sale can be found here. Insiders sold a total of 212,646 shares of company stock worth $36,791,022 over the last 90 days. 0.35% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on JNJ. Bank of America decreased their price objective on Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating on the stock in a report on Friday, October 14th. Credit Suisse Group assumed coverage on Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target on the stock. Sanford C. Bernstein decreased their price target on Johnson & Johnson from $194.00 to $190.00 in a research note on Wednesday, October 19th. Morgan Stanley decreased their price target on Johnson & Johnson from $174.00 to $170.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 19th. Finally, Barclays assumed coverage on Johnson & Johnson in a research note on Monday, October 17th. They issued an “equal weight” rating and a $175.00 price target on the stock. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $181.33.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $177.01 on Thursday. The firm has a market cap of $462.79 billion, a P/E ratio of 24.65, a P/E/G ratio of 3.49 and a beta of 0.57. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The business’s fifty day moving average is $168.35 and its two-hundred day moving average is $171.28.

Johnson & Johnson (NYSE:JNJGet Rating) last released its earnings results on Tuesday, October 18th. The company reported $2.55 earnings per share for the quarter, topping analysts’ consensus estimates of $2.49 by $0.06. The company had revenue of $23.79 billion during the quarter, compared to the consensus estimate of $23.44 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The firm’s quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.60 earnings per share. Equities research analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current fiscal year.

Johnson & Johnson announced that its Board of Directors has initiated a stock repurchase program on Wednesday, September 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to purchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board of directors believes its shares are undervalued.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Monday, November 21st. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.55%. Johnson & Johnson’s payout ratio is currently 62.95%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.